Background: Venous thromboembolism (VTE) is associated with significant morbid-
| INTRODUCTION
The kinetics of clot formation, clot structure, and clot firmness are of major importance for thrombus formation since they are associated with the recanalization of the obstructed vessels and thus, the risk of venous thromboembolism (VTE) recurrence. [1] [2] [3] [4] [5] Reduced plasma clot permeability has been associated with residual vein thrombosis which is an independent risk factor for recurrent VTE and postthrombotic syndrome (PTS). 6 Anticoagulant treatments aim to downregulate thrombin generation and potentially alter the kinetics of thrombus formation and clot quality.
The direct orally active anticoagulants (DOACs) differ by their target enzymes and the mechanism by which they inhibit thrombin generation. The antithrombin-dependent anticoagulants may selectively inhibit activated factor Xa (FXa), like fondaparinux or both FXa and thrombin, like low-molecular-weight heparins (LMWH) or unfractionated heparin (UFH). Rivaroxaban selectively and competitively inhibits free FXa and prothrombinase/clot-associated FXa through reversible interactions, thereby inhibiting thrombin generation and decreasing fibrin clot formation. [7] [8] [9] Fondaparinux, a methoxy form of the natural pentasaccharide sequence, is also a selective antithrombin (AT)-dependent FXa inhibitor. However, in contrast to rivaroxaban, fondaparinux does not inhibit prothrombin-bound or clot-associated FXa. [10] [11] [12] Dabigatran acts as a reversible direct thrombin inhibitor that specifically binds to both free and fibrin-bound thrombin. 13, 14 The
LMWHs are multi-targeted, AT-dependent, antithrombotic agents which differ substantially in their chemical structure, the anti-Xa/antiIIa ratio, and the inhibition rate of thrombin generation as compared to DOACs. [15] [16] [17] Their principal characteristics are summarized in Table 1 .
Despite the widespread clinical use of these agents and the detailed knowledge about their mechanism of action, their impact on clot formation kinetics and clot quality is poorly understood. Modelization of the effects of DOACs and AT-dependent antithrombotic agents on clot formation and structure could develop additional criteria for the classification of the anticoagulant agents.
We aim here to investigate different aspects of the mechanisms by which the direct inhibitors of FXa and thrombin and the AT-dependent anticoagulants alter thrombus growth. For this, we used thromboelastometry and thrombin generation assays to perform in vitro experiments by spiking normal human blood or plasma with clinically relevant concentrations of rivaroxaban, fondaparinux, dabigatran, and tinzaparin. To investigate any potential differences between the anti-Xa or anti-IIa activities of the AT-dependent agents and the respective specific activities of the direct inhibitors of FXa or thrombin, we performed mixing experiments of rivaroxaban and dabigatran in ratio which simulated those of the LMWH.
| MATERIALS AND METHODS

| Reagents
For thromboelastormery assays, recombinant human thromboplastin (Dade-Innovin) was purchased from Siemens Healthcare (Paris, 
| Sample preparation
Blood was collected from eight healthy volunteers (members of the laboratory staff) with atraumatic vein puncture using 22 G blood collection needles (Eclipse, BD Vacutainer Plymouth, UK) into siliconized Vacuette tubes (Greiner Bio-One GmbH, Kremsmunster, Austria) containing 1/9 (v/v) of buffered sodium citrate (3.2%).
Within 1 hour after venipuncture, blood from all donors was centrifuged twice at 2250 rpm for 15 minutes to obtain platelet-poor plasma (PPP). Samples of PPP were pooled and subsequently separated in 1 mL aliquots and stored at −80°C until assayed. Platelet rich plasma (PRP) was prepared separately after centrifugation of whole blood at 1070 rpm for 10 minutes and used for thrombin generation experiments. Platelet count in PRP samples was adjusted to 200 G/L using dilution with autologous plasma before being pooled.
The blood samples collected from the first four donors were individually spiked with rivaroxaban, dabigatran, tinzaparin, or fondaparinux. In separate experiments, whole blood was also spiked with associations of rivaroxaban and dabigatran. Samples were incubated with the studied anticoagulants for 30 minutes. The concentrations of rivaroxaban and dabigatran used for the thromboelastometry and thrombin generation experiments were 14, 42, 126, 252, and 700 ng/ mL plasma. The studied concentrations of fondaparinux were 0.4, 0.6, and 0.8 μg/mL plasma. The target plasma concentrations of
Essentials
• Direct or indirect FXa or thrombin inhibitors delay clot formation.
• We explored in vitro the impact of direct and AT-dependent inhibitors on clot characteristics.
• The inhibition of FXa by rivaroxaban or thrombin by dabigatran does not alter clot firmness.
• The AT-dependent antithrombotics suppress fibrin polymerization and decrease clot firmness.
tinzaparin were 0.05, 0.1, 0.2, 0.4, 0.6, and 0.8 anti-Xa IU/mL plasma.
These concentration ranges were selected according to the pharmacokinetics of the studied agents after administration of a therapeutic relevant dose.
18-20.
Associations of rivaroxaban and dabigatran were as follows:
7 ng/mL of rivaroxaban with 7 ng/mL of dabigatran (RD1), 21 ng/mL of rivaroxaban with 7 ng/mL of dabigatran (RD2), 21 ng/mL of both compounds (RD3), 90 ng/mL of both compounds (RD4), 180 ng/mL of rivaroxaban with 90 ng/mL of dabigatran (RD5), 180 ng/mL of both compounds (RD6), 500 ng/mL of rivaroxaban with 180 ng/mL of dabigatran (RD7), 500 ng/mL of both rivaroxaban and dabigatran (RD8).
| Thromboelastometry assay
Thromboelastometry was performed on ROTEM delta, Tem
Innovations GmbH, Werfen, (Munich, Germany). 
| Statistical analysis
Data are presented as mean ± SD of five separate experiments.
Statistical comparison was performed using the paired Student's t test to determine the significance of the differences between the values obtained under each experiment condition compared to the basal values Anti-Xa/anti-IIa ratio n/a n/a n/a 2 ± 0.5
Protein bound (%)
AT, antithrombin; FXa, activated factor X; FIIa, activated factor II; n/a, not applicable.
TA B L E 1 Principal characteristics of the antithrombotics rivaroxaban, fondaparinux, dabigatran, and tinzaparin for whole blood, PRP, and PPP. The unpaired Student's t test was used to control the differences between rivaroxaban, fondaparinux, dabi- 
| RESULTS
| Donors' characteristics
Principal clinical characteristics and individual values of basic blood tests of the healthy donors are shown in Table 2 . None of the donors had a personal history of thrombotic or bleeding disorder and none of the female donors used oral contraceptives. White blood cells count, platelet count, prothrombin time and activated partial thromboplastin time were in the normal range for all volunteers enrolled. Table 3 shows the concentrations of rivaroxaban, dabigatran, fondaparinux, tinzaparin, and the association of rivaroxaban and dabigatran which doubled the CT and increased by 20% the CFT.
| Effect of the antithrombotic agents on minimal TF-triggered whole-blood thromboelastometry
Representative thromboelastograms illustrating the dose-response of each compound are shown in Figure 1 .
| Factor Xa inhibitors
Rivaroxaban prolonged the CT in a concentration-dependent manner ( Figure 2A ). Rivaroxaban had no significant influence on the CFT while 20% prolongation of the CFT was obtained at concentrations higher than 126 ng/mL compared to control samples, although it was not statistically significant (P = .231) ( Figure 2B ). Even in the Values are expressed as mean ± standard deviation of five experiments. CT×2, the concentration required for doubling the clotting time, CFT×20%, the concentration required for increasing by 20% the clot formation time; CFT, clot formation time; CT, clotting time.
high-dose range, rivaroxaban had no detectable influence on the α- 
| Specific thrombin inhibitors
Dabigatran had a more pronounced effect on the CT than on CFT. At concentrations equal or higher than 252 ng/mL the effect of dabigatran on CT reached a plateau (Figure 2A ).
Dabigatran was able to prolong the CFT at concentrations as low as 42 ng/mL. However, higher concentrations, up to 252 ng/mL, had no further influence on the CFT ( Figure 2B ). At the highest concentration studied, dabigatran was able to increase the CFT 2.2-fold, compared to controls although the statistical significance of this finding was only marginal (P = .054). At the highest studied concentration, dabigatran was able to reduce the α-angle by 10% but had no significant influence on the MCF (Figure 2C , D).
| Combined inhibition of factor Xa and thrombin
Tinzaparin at concentrations equal or higher than 0.6 anti-Xa IU/mL completely abolished clot formation. Lower concentrations of tinzaparin prolonged both the CT and CFT and decreased the α-angle and MCF. The effect of tinzaparin was concentration-dependent ( Figure 2 , frames E, F, G, and H).
Associations of rivaroxaban and dabigatran amplified the effect on CT and CFT and reduced the α-angle significantly, compared to the effect of each agent alone ( Figure 3 , frames A, B, and C). In contrast, the effect of the associations did not significantly alter the MCF, even at the highest concentration ( Figure 3D ). In the presence of dabigatran, the concentration of rivaroxaban required to increase the CT by 2-fold and prolong the CFT by 20% was 48 and 36 ng/mL, respectively.
In comparison, in the presence of rivaroxaban, the concentrations of dabigatran required to increase the CT by 2-fold and prolong the CFT by 20% were 46.6 and 27 ng/mL, respectively (Table 3 ).
| Effect of the antithrombotic agents on thrombin generation in platelet-rich plasma
Representative thrombograms in the presence of increasing concentrations of each compound are shown in Figure 4 . 
| Factor Xa inhibitors
Rivaroxaban prolonged the LT and ttPeak and reduced the Peak, ETP, and MRI in a concentration-dependent manner. At the highest concentration (700 ng/mL) the Peak of thrombin was 28 ng/mL corresponding to about 16% of the Peak of thrombin for the control experiment. In the presence of the highest concentration of rivaroxaban, the time required for the generation of 10% of thrombin was about 30 minutes.
Fondaparinux at the lower concentration (0.4 μg/mL) had maximal effect on LT, ttPeak, Peak, and MRI ( Figure 4B ). At the highest concentration (0.8 μg/mL) the Peak of thrombin was 89 ng/mL corresponding to about 60% of the Peak of thrombin observed in the control experiment. In the presence of 0.8 μg/mL of fondaparinux the time required for the generation of 10% of thrombin was about 10 minutes.
| Specific thrombin inhibitors
Dabigatran significantly prolonged the LT in a concentrationdependent manner. At the highest concentration (700 ng/mL) the Peak of thrombin was 20 ng/mL corresponding to about 12% of the Peak of thrombin for the control experiment. In the presence of 700 ng/mL of dabigatran the time required for the generation of 10% of thrombin was about 40 minutes.
| Combined inhibition of factor
Xa and thrombin
Tinzaparin at concentrations ranging from 0.05 to 0.1 anti-Xa IU/mL did not significantly alter thrombin generation. On the other hand, at concentrations higher than 0.1 anti-Xa IU/mL tinzaparin significantly prolonged the LT and ttPeak and reduced the Peak, ETP and MRI.
Tinzaparin, at concentrations equal or higher than 0. 
| Effect of the antithrombotic agents on thrombin generation in platelet poor plasma
Representative thrombograms in the presence of increasing concentrations of each compound are shown in Figure 5 .
| Factor Xa inhibitors
Rivaroxaban completely suppressed thrombin generation at the highest studied concentration (700 ng/mL). At lower concentrations, rivaroxaban had a more potent effect on the ttPeak com- 
| Specific thrombin inhibitors
Dabigatran completely abolished thrombin formation at the highest studied concentration (700 ng/mL). At concentrations below 700 ng/mL, dabigatran prolonged the LT and ttPeak in a concentration-dependent manner. At a concentration of 252 ng/mL, the Peak of thrombin was 137 ng/mL corresponding to about 45% of the Peak of thrombin for the control experiment. In the presence of 252 ng/mL dabigatran, the time required for the generation of 10% of thrombin was about 19 minutes.
| Combined inhibition of factor Xa and thrombin
Tinzaparin only marginally prolonged the LT at the lowest concentrations. In contrast, for concentrations up to 0.4 anti-Xa IU/mL F I G U R E 4 Representative thrombograms of rivaroxaban, fondaparinux, dabigatran, tinzaparin and the association of rivaroxaban and dabigatran on platelet rich plasma (PRP) thrombin generation (TGA). Plasma samples were spiked with the compounds as indicated in the graph. RD2, 21 ng/mL of rivaroxaban with 7 ng/ mL of dabigatran; RD3, 21 ng/mL of both; RD4, 90 ng/mL of both; RD5, 180 ng/mL of rivaroxaban with 90 ng/mL of dabigatran Rivarovaban in PRP 0 14 ng/mL 42 ng/mL 126 ng/mL 252 ng/mL 700 ng/mL 100 Association of rivaroxaban and dabigatran had added effect on the LT and ttPeak although this effect was only evident when the two drugs were combined at concentrations of 90 ng/mL or higher.
At the highest concentrations of rivaroxaban (500 ng/mL), thrombin generation was suppressed. At concentrations of 180 ng/mL for both compounds, the Peak of thrombin was 70 ng/mL corresponding to about 40% of the Peak of thrombin for the control experiment.
In the presence of the above mentioned concentrations, the time required for the generation of 10% of thrombin was about 36 minutes.
| DISCUSSION
The present study explored in vitro the impact of the LMWH tinzaparin, the antithrombin-dependent FXa inhibitor fondaparinux, and the specific and direct inhibitors of FXa (rivaroxaban) and thrombin (dabigatran) on clot formation kinectics and clot firmness. All agents delayed thrombus formation in a concentration-dependent manner; however, they differed substantially with regard to their impact on fibrin polymerization and clot firmness. Previously, our group showed that whole blood thromboelastometry assessment using a low TF concentration was sensibly influenced by LMWH and fondaparinux. 22, 23 However, when the test was performed in the presence of high TF concentration (EXTEM) or contact system activator (INTEM) was less sensitive to the activity of these agents. 24, 25 Comparison of the data obtained by thrombin generation assessment in PPP or PRP with those obtained by the thromboelastometric study in whole blood shows that the delay in clot formation is principally linked to the prolongation of the initiation phase of thrombin generation and to the delay of the propagation phase.
The inhibitory potency of the antithrombotic agents on thrombin generation was significantly higher in PPP compared to PRP. The property of platelets to inhibit the antithrombotic activity of UFH and to a lesser degree LMWHs has been well described and is principally mediated by platelet factor 4 (PF4). 26 Fondaparinux, rivaroxaban, and dabigatran do not interfere with PF4; thus, this outcome could be attributed to an increased efficiency of the enzymatic complexes (prothrombinase and intrinsic tenase) formed in the F I G U R E 5 Representative thrombograms of rivaroxaban, fondaparinux, dabigatran, tinzaparin and the association of rivaroxaban and dabigatran on platelet poor plasma (PPP) thrombin generation (TGA). Plasma samples were spiked with the compounds as indicated in the graph. RD2, 21 ng/mL of rivaroxaban with 7 ng/ mL of dabigatran; RD3, 21 ng/mL of both; RD4, 90 ng/mL of both; RD5, 180 ng/mL of rivaroxaban with 90 ng/mL of dabigatran; RD6, 180 ng/mL of both of the incorporation of LMWH chains into the fiber network. 34 To the best of our knowledge this is the first report to indicate that the minimum pentasaccharide domain required for AT-mediated inhibition of FXa is also required for fibrin polymerization inhibition.
These data lead to the proposition of additional criteria for the classification of the anticoagulant drugs according to their effect on clot formation kinetics and clot quality.
Some limitations of the study should be acknowledged since they do not allow extrapolation of these findings in the clinical field. Blood samples were obtained from healthy volunteers; thus, the present study does not allow the evaluation of the impact of some pathological conditions, such as inflammation, on the effect of the antithrombotic agents on clot formation and thrombin generation. Moreover, the in vitro design of the study favored the anti-IIa activity of the LMWH tinzaparin. Indeed, in vivo the elimination of the anti-IIa activity is rapid, whereas in a static in vitro system this activity persists at the same level throughout the whole experimental period.
In 
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